IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
IONIS PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$44.38+1.44 (+3.35%)
Close on Oct 19, 2026
- Market cap
- $7.34B
- P/E (TTM)
- –
- Dividend yield
- –
IONIS PHARMACEUTICALS INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Operations [Member] | $943.71M | $705.14M | $787.65M | $587.37M | – | – | – | – | – | – | 100.0% | +33.8% |
| Akcea Therapeutics [Member] | – | – | – | – | – | $152.32M | $488.54M | $64.87M | $43.40M | $0 | – | – |
| Ionis [Member] | – | – | – | – | – | $622.94M | $858.65M | $641.94M | $525.19M | $385.42M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Akcea Therapeutics [Member] | – | – | – | – | – | -$237.26M | $38.07M | -$230.82M | -$120.47M | -$83.51M | – |
| Ionis [Member] | – | – | – | – | – | $59.29M | $335.44M | $261.73M | $151.40M | $63.23M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and Development Revenue [Member] | $507.86M | $412.06M | $479.06M | $284.01M | $468.06M | $364.57M | – | – | – | – | 53.8% | +23.2% |
| Collaborative Agreement Revenue [Member] | $465.79M | $332.65M | $352.66M | $207.22M | $468.06M | $364.57M | – | – | – | – | 49.4% | +40.0% |
| Commercial Revenue [Member] | $435.85M | $293.08M | $308.59M | $303.36M | $342.40M | $364.70M | $352.45M | $254.92M | $120.01M | $22.77M | 46.2% | +48.7% |
| Royalty Revenue [Member] | $285.53M | $257.31M | $272.80M | – | – | – | – | – | – | – | 30.3% | +11.0% |
| SPINRAZA Royalties [Member] | $212.28M | $216.09M | $240.38M | $242.31M | $267.78M | $286.58M | $292.99M | $237.93M | – | – | 22.5% | -1.8% |
| Product Sales, Net [Member] | $115.32M | $0 | $0 | $30.05M | $55.50M | $70.00M | $42.25M | $2.24M | $0 | $0 | 12.2% | – |
| TRYNGOLZA Sales [Member] | $107.53M | $0 | $0 | – | – | – | – | – | – | – | 11.4% | – |
| WAINUA Royalties [Member] | $49.09M | $20.21M | $0 | $0 | – | – | – | – | – | – | 5.2% | +142.9% |
| WAINUA Joint Development Revenue [Member] | $42.08M | $79.42M | $126.40M | $76.79M | $0 | – | – | – | – | – | 4.5% | -47.0% |
| Other Commercial Revenue [Member] | $35.00M | $35.77M | $35.79M | $61.04M | $74.62M | – | – | – | – | – | 3.7% | -2.1% |
| Other Royalties [Member] | $24.16M | $21.01M | $32.42M | – | – | – | – | – | – | – | 2.6% | +15.0% |
| DAWNZERA Sales [Member] | $7.79M | $0 | $0 | – | – | – | – | – | – | – | 0.8% | – |
| Licensing and Other Royalty Revenue [Member] | – | – | $33.30M | $30.99M | $19.12M | $8.12M | $17.21M | $14.76M | $7.47M | $21.88M | – | – |
| SPINRAZA Royalties [Member] | – | – | – | – | – | – | $292.99M | $237.93M | $112.54M | $883.00K | – | – |
| R&D Revenue [Member] | – | – | – | – | $468.06M | $364.57M | $770.15M | $344.75M | $394.17M | $350.01M | – | – |
| Eplontersen Joint Development Revenue [Member] | – | – | – | $76.79M | $0 | $0 | – | – | – | – | – | – |
| Other Revenue [Member] | – | $22.59M | $33.30M | $30.99M | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Ionis Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.